WOLLVAC Poultry Vaccine Solution

Poultry Avian Influenza Vaccine

WOLLVAC provides avian influenza vaccine solutions for poultry, focusing on H9N2 low pathogenic avian influenza, regional clade matching, multivalent poultry vaccine programs and technical support for farms, veterinarians, distributors and importers.

H9N2

H9N2

Main low pathogenic AI subtype

4.1

4.1.a / 4.1.b

Middle East clade-oriented vaccine antigens

Titer

>=3x10^9.0

EID50 / 0.1 mL before inactivation

Low

<=10 EU/mL

Low endotoxin treatment direction

What Is H9N2 Avian Influenza in Poultry?

Avian influenza viruses belong to type A influenza viruses of the Orthomyxoviridae family. The virus particles are spherical, approximately 80-120 nanometers in diameter, and are enveloped. The envelope contains two major surface proteins: hemagglutinin (HA) and neuraminidase (NA).

Multiple HA and NA combinations can form different avian influenza virus subtypes. The H9 subtype is generally classified as low pathogenic avian influenza, with H9N2 being the predominant subtype.

H9N2 itself may show relatively weak direct pathogenicity, but it can reduce flock resistance and increase the risk of mixed infections with Newcastle disease, infectious bronchitis and bacterial diseases, which may result in severe production losses.

Key point: Low pathogenicity does not mean low risk. H9N2 control should combine vaccination, biosecurity, feeding management and monitoring of secondary infections.

Clinical Signs And Production Impact

Why H9N2 Is a Hidden Poultry Production Risk

H9N2 infection can weaken flock resistance and is often associated with respiratory lesions, reduced hatchability and mixed infection problems in poultry production.

01

Lower Hatchability

H9N2 challenge may be associated with reduced hatching performance, especially when mixed infections or management stress exist.

02

Pulmonary Lesions

Poultry may show pulmonary congestion and consolidation, affecting respiratory performance and flock condition.

03

Bronchial Hemorrhage

Respiratory tract damage can increase susceptibility to other pathogens and worsen disease outcomes.

04

Bronchial Obstruction

Obstruction and respiratory distress may appear when H9N2 combines with other respiratory pathogens.

Clinical observation examples: bronchial obstruction, bronchial hemorrhage, pulmonary congestion and reduced hatchability.

H9N2 should be managed together with respiratory disease complex prevention and flock immune status monitoring.

Regional Clade Matching Matters for H9N2 Vaccine Selection

H9N2 strains circulating in different regions may belong to different clades. According to the supplied technical material, China-related strains are mainly associated with H9.4.2 lineages, while the Middle East and nearby regions are associated with the H9.4.1 clade.

Significant clade differences may reduce cross-protection. Therefore, vaccine selection should consider regional prevalent strains, field challenge history and product antigen matching.

WOLLVAC H9 series vaccines use inactivated antigens from H9N2 subtype clade 4.1.a and 4.1.b, helping meet vaccine needs in the Middle East and nearby markets where H9.4.1-related strains are a key concern.

Distributor communication point: Ask customers about country, local field strain pressure, current vaccination program and whether H9.4.1-oriented product information is required.

Product Selection Guide

How to Choose an Avian Influenza Vaccine Direction

Select vaccine products according to local H9N2 clade pressure, co-infection risks, bird type, vaccination history, product registration status and farm management conditions.

Field Situation

Recommended Product Direction

Main Purpose

Buyer Concern Addressed

H9N2 is the main concern

WOLLVAC Avian Influenza H9 Series Vaccine

Targeted H9N2 low pathogenic avian influenza prevention

Regional strain matching and H9N2 control

H9N2 + Newcastle Disease pressure

ND + AI vaccine direction

Combined ND and AI prevention program

Simpler respiratory vaccine portfolio

H9N2 + IB respiratory challenge

ND + IB + AI vaccine direction

Broader respiratory disease control

Mixed infection and respiratory loss reduction

H9N2 + FADV field pressure

ND + AI + FADV vaccine direction

Combined AI and adenovirus-related pressure support

FADV-related production and mortality concerns

Layer / breeder production concern

ND + IB + EDS + AI vaccine direction

Respiratory and egg-production program support

Egg drop, hatchability and production stability

Complex disease pressure

ND + IB + AI + FADV + IBD vaccine direction

Comprehensive multivalent poultry vaccine program

Multiple disease risks and portfolio simplification

Core Technology

WOLLVAC H9 Series Vaccine Technology Highlights

The WOLLVAC H9 series is designed around antigen matching, low-stress formulation and stable emulsification to support poultry vaccine program performance.

01

Endotoxin Treatment

Endotoxin levels are controlled at <=10 EU/mL, helping reduce endotoxin-induced stress during vaccination communication.

02

Composite Oil Adjuvant

French-origin imported adjuvant direction with vaccine viscosity below 30 cP, supporting flowability and reduced vaccination stress.

03

Low-Temperature Shear Emulsification

Low-temperature high-speed shear emulsification helps produce uniform and fine particles with good stability.

04

Low Formaldehyde Inactivation

Low formaldehyde inactivation process with final formaldehyde concentration at 0.8 per mille to help reduce side reactions.

Reference material: recovery status of subcutaneous / muscular tissues 30 days after vaccination showed no abnormalities.

Reference material: uniform and fine particle size, with average particle size around 1.13 um and good stability.

Prevention & Control Strategy

H9N2 Control Requires More Than Vaccination

A practical H9N2 prevention program should combine vaccine selection, biosecurity, feeding management and reduction of environmental stress.

01

Improve Biosecurity

Establish strict isolation systems, physical barriers, vehicle/personnel disinfection and regular farm disinfection to reduce virus survival and spread.

02

Strengthen Feeding Management

Manage temperature, humidity and ventilation to reduce cold stress and improve flock resistance during H9N2 risk periods.

03

Control Mixed Infections

Monitor Newcastle Disease, Infectious Bronchitis and bacterial disease risks because mixed infections can worsen H9N2 outcomes.

Who This Page Is For

Avian Influenza Vaccine Support for Different Buyers

WOLLVAC supports farms, veterinary service providers, distributors and importers with H9N2 product information, vaccine portfolio recommendation and registration-related communication.

FM

Poultry Farms

Request H9N2 vaccine directions and multivalent poultry vaccine program communication for flock health management.

VET

Veterinary Teams

Discuss disease pressure, vaccination history and technical product information for poultry respiratory disease programs.

DI

Distributors

Build a regional avian influenza vaccine portfolio with H9N2 and multivalent poultry vaccine product directions.

IM

Importers

Request product specifications, label information, registration-related documents and cooperation details.

Need H9N2 Vaccine Information for Your Market?

Tell us your country, poultry type, H9N2 strain concern and current vaccination program. WOLLVAC will help you identify suitable vaccine directions.

FAQ

Avian Influenza Vaccine FAQ

Common questions from poultry farms, veterinarians, distributors and importers when selecting avian influenza vaccines.

What is H9N2 low pathogenic avian influenza?

H9N2 is a low pathogenic avian influenza subtype. Although its direct pathogenicity can be relatively weak, it may reduce flock resistance and increase the risk of mixed infections with Newcastle Disease, Infectious Bronchitis and bacterial diseases.

The main risk is not only direct infection, but also immune suppression, respiratory damage and secondary mixed infection. These factors can lead to reduced hatchability, respiratory lesions, lower production performance and greater flock losses.

H9N2 strains circulating in different regions may belong to different clades. If the vaccine antigen does not match the prevalent strain well, cross-protection may be reduced. Customers should consider local field strain pressure and regional epidemiology before choosing a vaccine direction.

According to the supplied product material, WOLLVAC Avian Influenza H9 series vaccine contains inactivated H9N2 subtype clade 4.1.a and 4.1.b antigens, both with viral titers >=3×10^9.0 EID50 / 0.1 mL before inactivation.

Yes. WOLLVAC poultry vaccine directions include H9N2-related monovalent and multivalent options such as ND + AI, ND + IB + AI, ND + AI + FADV, ND + IB + EDS + AI and broader multivalent vaccine directions.

If H9N2 is the primary risk, a targeted H9 series vaccine may be considered. If H9N2 is accompanied by ND, IB, FADV, IBD or production-related problems, multivalent vaccine directions may be more suitable. Final selection should follow local disease pressure, registration status and veterinary guidance.

Yes. Distributors can request product details, specifications, label information, storage conditions and registration-related communication. Exact documents depend on product availability and destination-market regulatory requirements.

No. H9N2 prevention should combine suitable vaccination, strict biosecurity, environmental management, ventilation control, feeding management and monitoring of secondary infections.

Request Avian Influenza Vaccine Product Information

Submit your target country, poultry type, H9N2 disease concern and product requirements. WOLLVAC will help you identify suitable avian influenza vaccine directions and provide product information.

Support: H9N2 Product Details / Multivalent Vaccine Options / Label / Specification / Registration Documents

Suitable For: Poultry Farms, Veterinarians, Distributors and Importers

Email: info@wollvac.com

Get H9N2 Vaccine Details

报错: 未找到这个表单

Replace xxx with the real Contact Form 7 form ID after import.

滚动至顶部